It has been shown that combined TBK1/MEK inhibitors synergistically enhance apoptosis in several model systems with mutated RAS, including lung cancer, melanoma cells, as well as in BRAF mutant melanoma cells, resistant to MEK (62, 64–66), warranting further investigation of combined use of TBK1 and MEK inhibitors also in MM. The gene discussed is BRAF; the disease is lung cancer.